Tilray supports trial to study medical cannabis in glioblastoma cancer treatment

Tilray Medical announced their contribution to an independent clinical trial to research the efficacy of medical cannabis as a treatment for glioblastoma, a severe form of brain cancer. The clinical trial will be conducted in Spain, recruiting 30 patients from eight specialized neuro-oncology medical sites, in partnership with renowned scientists from the Spanish Research Group of Neuro-Oncology and the Complutense University of Madrid, with Tilray Medical providing the pharmaceutical-grade medical cannabis for the trial for administration to patients. The trial is funded by the Medical Cannabis Bike Tour Foundation charity and is scheduled to commence at University Hospital 12 de Octubre, on September 5, 2023. Led by esteemed coordinating investigator Dr. Juan Manuel Sepulveda Sanchez from GEINO, the clinical trial is a Phase I, open-label, multicenter, intrapatient dose-escalation to evaluate the safety and profile of Tilray Medical’s T10:C10 extract, in conjunction with temozolomide and radiotherapy for newly-diagnosed Glioblastoma patients.